PURPOSE: A phage-displayed peptide TGN was used as a targeting motif to help the delivery of NAP-loaded nanoparticles across the blood-brain barrier (BBB), which sets an obstacle for brain delivery of NAP in vivo. METHODS: Intracerebroventricular injection of Aβ₁₋₄₀ into mice was used to construct in vivo model of Alzheimer's disease. The water maze task was performed to evaluate the effects of the NAP formulations on learning and memory deficits in mice. The neuroprotective effect was tested by detecting acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) activity and conducting histological assays. RESULTS: Intravenous administration of NAP-loaded TGN modified nanoparticles (TGN-NP/NAP) has shown better improvement in spatial learning than NAP solution and NAP-loaded nanoparticles in Morris water maze experiment. The crossing number of the mice with memory deficits recovered after treatment with TGN-NP/NAP in a dose dependent manner. Similar results were also observed in AChE and ChAT activity. No morphological damage and no detectable Aβ plaques were found in mice hippocampus and cortex treated with TGN-NP/NAP. CONCLUSIONS: TGN modified nanoparticles could be a promising drug delivery system for peptide and protein drug such as NAP to enter the brain and play the therapeutic role.
PURPOSE: A phage-displayed peptide TGN was used as a targeting motif to help the delivery of NAP-loaded nanoparticles across the blood-brain barrier (BBB), which sets an obstacle for brain delivery of NAP in vivo. METHODS: Intracerebroventricular injection of Aβ₁₋₄₀ into mice was used to construct in vivo model of Alzheimer's disease. The water maze task was performed to evaluate the effects of the NAP formulations on learning and memory deficits in mice. The neuroprotective effect was tested by detecting acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) activity and conducting histological assays. RESULTS: Intravenous administration of NAP-loaded TGN modified nanoparticles (TGN-NP/NAP) has shown better improvement in spatial learning than NAP solution and NAP-loaded nanoparticles in Morris water maze experiment. The crossing number of the mice with memory deficits recovered after treatment with TGN-NP/NAP in a dose dependent manner. Similar results were also observed in AChE and ChAT activity. No morphological damage and no detectable Aβ plaques were found in mice hippocampus and cortex treated with TGN-NP/NAP. CONCLUSIONS: TGN modified nanoparticles could be a promising drug delivery system for peptide and protein drug such as NAP to enter the brain and play the therapeutic role.
Authors: L Beni-Adani; I Gozes; Y Cohen; Y Assaf; R A Steingart; D E Brenneman; O Eizenberg; V Trembolver; E Shohami Journal: J Pharmacol Exp Ther Date: 2001-01 Impact factor: 4.030
Authors: Illana Gozes; Bruce H Morimoto; Jacqueline Tiong; Anthony Fox; Karole Sutherland; David Dangoor; Miriam Holser-Cochav; Karin Vered; Paul Newton; Paul S Aisen; Yasuji Matsuoka; Christopher H van Dyck; Leon Thal Journal: CNS Drug Rev Date: 2005
Authors: Yasuji Matsuoka; Audrey J Gray; Chiho Hirata-Fukae; S Sakura Minami; Emily Graeme Waterhouse; Mark P Mattson; Frank M LaFerla; Illana Gozes; Paul S Aisen Journal: J Mol Neurosci Date: 2007 Impact factor: 2.866
Authors: Surya K Mallapragada; Timothy M Brenza; JoEllyn M McMillan; Balaji Narasimhan; Donald S Sakaguchi; Anup D Sharma; Svitlana Zbarska; Howard E Gendelman Journal: Nanomedicine Date: 2015-01-31 Impact factor: 5.307
Authors: Madhoosudan A Patil; Arun K Upadhyay; Laura Hernandez-Lagunas; Ryan Good; Todd C Carpenter; Carmen C Sucharov; Eva Nozik-Grayck; Uday B Kompella Journal: Artif Cells Nanomed Biotechnol Date: 2018-11-19 Impact factor: 5.678
Authors: Dhirender Singh; JoEllyn M McMillan; Alexander V Kabanov; Marina Sokolsky-Papkov; Howard E Gendelman Journal: Nanomedicine (Lond) Date: 2014-04 Impact factor: 5.307